Skip to content

Study on rocuronium bromide and its antagonist metabolism in laparoscopic adrenalectomy under general anesthesia

Study on rocuronium bromide and its antagonist metabolism in laparoscopic adrenalectomy under general anesthesia

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400089951
Enrollment
Unknown
Registered
2024-09-20
Start date
2024-10-01
Completion date
Unknown
Last updated
2024-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adrenal tumor

Interventions

Non-functional use of neostigmine and sodium gluconate (NFNS group):At PTC=1-2, neostigmine 20 µg/kg+ atropine 10 µg/kg was injected intravenously, and at TOF=1-2, Shugeng glucose sodium 2 mg/kg was i
Non-functional use of Shugeng sodium gluconate group (NFS):At PTC=1-2, intravenous injection of Shugeng glucose sodium 4 mg/kg.
Functional use of neostigmine and sodium gluconate (FNS group):At PTC=1-2, neostigmine 20 µg/kg+ atropine 10 µg/kg was injected intravenously, and at TOF=1-2, Shugeng glucose sodium 2 mg/kg was inject
Functional use of Shugeng glucose sodium group (FS group):At PTC=1-2, intravenous injection of Shugeng glucose sodium 4 mg/kg.

Sponsors

The First Affiliated Hospital of Zhengzhou University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1) Preoperative imaging examination of American Society of Anesthesiologists (ASA, Grade I ~ II) found adrenal space occupying lesions; 3) Adrenal tumor treated by laparoscopic general anesthesia; 4) There are pathological and morphological indexes after operation; 5) Complete clinical data. 6) Age > 18 years old.

Exclusion criteria

Exclusion criteria: 1) allergic to experimental drugs and contraindications; 2) Incomplete or lacking clinical data; 3) Patients with adrenal metastasis, (4) hand or upper limb disability, morbid obesity (body mass index = 30kg/m2), (5) preoperative use of antibiotics and other drugs that interfere with neuromuscular transmission, (6) refusal to participate in this study.

Design outcomes

Primary

MeasureTime frame
Rocuronium dosage per unit time of 10kg body weight during operation (mg/10kg*h);

Secondary

MeasureTime frame
Time from the first dose of muscle relaxant to the recovery of TOFr to 0.7;Time from the first dose of muscle relaxant to TOFr recovery to 0.9;Time from the first dose of muscle relaxant to the removal of tracheal catheter;

Countries

China

Contacts

Public ContactHong Ye

The First Affiliated Hospital of Zhengzhou University

shiliushu2012@163.com+86 152 2516 2086

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026